Cost-effectiveness Analysis of Pembrolizumab monotherapy and Chemotherapy in the Non-small-cell Lung Cancer with different PD-L1 Tumor Proportion Scores

Lung cancer is the leading cause of cancer-related deaths worldwide and can be broadly classified into two types: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The former represents 85% of all lung cancer [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are aggressive neuroendocrine tumors with poor survival rates [1 –3]. For stage IV SCLC, treatment has not advanced significantly over the last decades and consists of palliative chemotherapy. The same applies to stage IV LCNEC, were no standard treatment exists and palliative chemotherapy with SCLC and non-small cell lung cancer (NSCLC) regimens are both deeme d appropriate [4]. Recently, targeted therapy focusing on delta like protein 3 (DLL3) has received attention to improve outcomes for SCLC and LCNEC [5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Purpose of review The current article reviews the state of art of prevention strategies for brain metastases from solid tumors and touches both old pivotal studies and new directions of personalized molecular approaches. Recent findings Prophylactic cranial irradiation (PCI) has a definite role in the prevention of relapse into the brain for patients with small cell lung cancer (SCLC) responding to chemotherapy and radiotherapy as it prolongs overall survival (OS). However, the risk of late cognitive deficit following whole brain radiotherapy (WBRT) in this patient population is still not well known. Conversely, PCI s...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: BRAIN AND NERVOUS SYSTEM: Edited by Marc Sanson Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31381177 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research
Lung cancer is one of the leading causes of cancer-related deaths in the world. In 2012, lung cancer was responsible for approximately 1.6 million deaths worldwide [1]. Lung cancer may be broadly divided into small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), with many distinct histology subtypes in the latter [2]. In contrast to SCLC, where chemotherapy provides the mainstay of treatment with mostly palliative intent, surgery is routinely performed in early stage NSCLC with a curative intent [2,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This article reviewed the predictive value of TMB and its limitations in the field of immunotherapy for lung cancer. DOI: 10.3779/j.issn.1009-3419.2019.06.08
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
nning Schmidt Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on histology, there are two major subtypes: Non-small cell lung cancer (NSCLC) (the more frequent subtype), and small cell lung cancer (SCLC) (the more aggressive one). Even though SCLC, in general, is a chemosensitive malignancy, relapses following induction therapy are frequent. The standard of care treatment of SCLC consists of platinum-based chemotherapy in combination with etoposide that is subsequently enhanced by PD-L1-inhibiting atezolizumab in the extensive-stage disease, as the addition of immune-checkpoint inhibit...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Lung cancer is the leading cause of cancer related mortality globally and is classified as either Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC) upon pathology review. [1,2] The main histologic types of NSCLC include squamous cell carcinoma and adenocarcinoma. [2] The majority of patients have non-curable disease stage at the time of diagnosis. Advances in systemic treatments including chemotherapy, targeted therapies and immune check point inhibitors have improved prognosis in recent years.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: Our data supports that never/ever smoker patients with small-cell lung cancer have better prognosis compared to their smoker counterparts. Further, patients with never/ever smoking history who present with small-cell lung cancer have a different mutation profile compared with smokers, including a high frequency of EGFR, MET, and SMAD4 mutations. Further studies are required to assess whether the differential mutation profile is a consequence of a diverse pathological mechanism for disease onset. Introduction Lung cancer is the most common neoplasia worldwide. Aside from the high incidence, lung cancer a...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, 7 patients with transformation of SCLC from advanced lung adenocarcinoma (ADC) were analyzed retrospectively and the clinical pathology, imaging characteristics and treatment were analyzed. We identified 7 patients with primary lung ADC that showed transformation to SCLC on second biopsy during a 6-year period. Clinicopathologic information was analyzed and EGFR mutation results were performed in initial biopsy samples. Seven patients showed transformation from ADC to SCLC, of which 6 patients were 19 del EGFR mutation, only 1 patient is L858R mutations. The imaging forms did not have the typical imaging f...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Our study shows that retinoblastoma (RB1) mutation is associated with decreased overall survival in patients with locally advanced and advanced non small cell lung cancer. We also show thatRB1 mutation correlates with lack of response to immunotherapy. AbstractThe retinoblastoma gene (RB1) encodes the retinoblastoma (RB) pocket protein that plays an important role in cell cycle progression. Here we determine the frequency and prognostic significance ofRB1 mutation in non small cell lung cancer (NSCLC), restricting inclusion to Stage III and IV patients with linked genomic and clinical data. The primary outcome was median o...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Small Cell Lung Cancer